HCWB vs. SGTX, TTOO, LMNL, ENLV, CYAD, ALIM, RIGL, CNTX, PRQR, and SGMT
Should you be buying HCW Biologics stock or one of its competitors? The main competitors of HCW Biologics include Sigilon Therapeutics (SGTX), T2 Biosystems (TTOO), Liminal BioSciences (LMNL), Enlivex Therapeutics (ENLV), Celyad Oncology (CYAD), Alimera Sciences (ALIM), Rigel Pharmaceuticals (RIGL), Context Therapeutics (CNTX), ProQR Therapeutics (PRQR), and Sagimet Biosciences (SGMT). These companies are all part of the "medical" sector.
Sigilon Therapeutics (NASDAQ:SGTX) and HCW Biologics (NASDAQ:HCWB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, media sentiment, risk, valuation, community ranking, dividends and earnings.
Sigilon Therapeutics has a net margin of -171.29% compared to Sigilon Therapeutics' net margin of -697.53%. HCW Biologics' return on equity of -83.07% beat Sigilon Therapeutics' return on equity.
3.0% of HCW Biologics shares are held by institutional investors. 6.5% of Sigilon Therapeutics shares are held by company insiders. Comparatively, 49.9% of HCW Biologics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Sigilon Therapeutics has a beta of 4.12, meaning that its stock price is 312% more volatile than the S&P 500. Comparatively, HCW Biologics has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500.
Sigilon Therapeutics received 18 more outperform votes than HCW Biologics when rated by MarketBeat users. However, 100.00% of users gave HCW Biologics an outperform vote while only 58.54% of users gave Sigilon Therapeutics an outperform vote.
HCW Biologics has lower revenue, but higher earnings than Sigilon Therapeutics. Sigilon Therapeutics is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks.
In the previous week, HCW Biologics had 2 more articles in the media than Sigilon Therapeutics. MarketBeat recorded 2 mentions for HCW Biologics and 0 mentions for Sigilon Therapeutics. Sigilon Therapeutics' average media sentiment score of 1.43 beat HCW Biologics' score of 0.00 indicating that HCW Biologics is being referred to more favorably in the news media.
Sigilon Therapeutics currently has a consensus target price of $21.00, suggesting a potential downside of 6.54%. Given HCW Biologics' higher possible upside, analysts plainly believe Sigilon Therapeutics is more favorable than HCW Biologics.
Summary
HCW Biologics beats Sigilon Therapeutics on 9 of the 16 factors compared between the two stocks.
Get HCW Biologics News Delivered to You Automatically
Sign up to receive the latest news and ratings for HCWB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HCWB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
HCW Biologics Competitors List
Related Companies and Tools
